0 products, total $0.+86-400-890-9989      Login |  Register 中文한국어

Browse By Molecule:

Your Position: Home > Antibody > Rabbit MAb Antibody > KLK-11 / Kallikrein-11 Antibody (Rabbit Monoclonal Antibody)

KLK-11 / Kallikrein-11 Antibody (Rabbit Monoclonal Antibody) PDF Download

Catalog Size (Price) Quantity In Stock Operation Other Information
10767-R121
  YES          

Kallikrein-Related Peptidase 11 ( KLK-11 / Kallikrein 11 ) Antibody

  Order or Inquire for KLK11 Antibody product
  Detection limit is 0.125 ng/lane in WB
  Detection limit is 0.0049 ng/well in ELISA
 

KLK-11 / Kallikrein 11 Antibody Product Information

Immunogen :

Recombinant human KLK-11 protein ( Catalog#10767-H08H )

Antibody Type : Rabbit Monoclonal Antibody ( Rabbit mAb Service Platform )

Clone ID :

121

Ig Type :

Rabbit IgG

Formulation : 0.2 μm filtered solution in PBS with 5% trehalose
Preparation :

This antibody was obtained from a rabbit immunized with purified, human cell-derived, recombinant human KLK11 / Kallikrein 11 ( rh KLK-11 ; Catalog#10767-H08H ; Met 1 - Asn 250 ; NP_006844.1 ).

KLK-11 / Kallikrein 11 Antibody Usage Guide

Specificity :

Human KLK-11 / Kallikrein 11

Western blot : This antibody can be used at 1 - 2 μg/mL with the appropriate secondary reagents to detect human KLK11  in WB. Using a DAB detection system, the detection limit for human KLK11 is approximately 0.125 ng/lane under non-reducing conditions and reducing conditions
Direct ELISA : This antibody can be used at 0.1 - 0.2 μg/mL with the appropriate secondary reagents to detect human KLK11. The detection limit for human KLK11 is 0.0049 ng/well
Storage : This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

KLK-11 / Kallikrein 11 Antibody Related Products & Topics

Related Areas:

Enzyme>>Protease & Regulator>>Serine Protease & Regulator>>Kallikrein>>KLK11/Kallikrein 11

Cancer>>Angiogenesis>>Kallikrein>>KLK11/Kallikrein 11

Proteins:

Molecule Species Description //For Detailed Info. and Price------CLICK! Cat. No
KLK11/Kallikrein 11 Human KLK11/Kallikrein 11 Protein, Recombinant 10767-H08H
KLK11/Kallikrein 11 Mouse KLK11 / Kallikrein-11 Protein, Recombinant 50919-M08H

Antibodies:

Molecule Application Description //For Detailed Info. and Price------CLICK! Cat. No
Human
KLK11/Kallikrein 11
WB, ELISA Rabbit Monoclonal Antibody 10767-R121
Human
KLK11/Kallikrein 11
WB, ELISA Rabbit Polyclonal Antibody 10767-RP01
Human
KLK11/Kallikrein 11
WB, ELISA Rabbit Polyclonal Antibody (Antigen Affinity Purified) 10767-RP02
Human
KLK11/Kallikrein 11
WB, ELISA KLK11 / Kallikrein 11 Antibody 10767-MM05

KLK-11 / Kallikrein 11 Antibody Background

Kallikrein-related peptidase 11 (KLK11), also known as hippostasin, trypsin-like serine protease and PRSS20, is a member of human tissue kallikrein family. It is a subgroup of serine proteases with diverse physiological functions, which is implicated in carcinogenesis and some with potential that serving as novel biomarkers for ovarian and prostate cancer and other diseases. The KLK11 gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. Two alternatively spliced forms exist, resulting in 250 (isoform 1) and 282 (isoform 2) amino acid sequences. Isoform 2 is identical to isoform 1, except for an inserted 32 amino acid segment. Isoform 1 is predominantly expressed in brain whereas isoform 2 is preferentially expressed in prostate. 

References

  1. Yoshida, S. et al., 1998, Biochim. Biophys. Acta 1399: 225-8.
  2. Yousef, GM. et al., 2000,Genomics 63: 88-96.
  3. Mitsui, S. et al., 2000, Biochem. Biophys. Res. Commun. 272: 205-11.
  4. Gan, L. et al., 2000, Gene 257:119-30.
  5. Yousef, GM. et al., 2001, Endocrine Rev. 22:184-204.
  6. Kong, WJ. et al., 2006, J Mol Med. Jan. 84 (1): 29-36.